NeuroGlove Anxiety and Depression Study

NeuroGlove LLC10 enrolled

Overview

This is a prospective, homebased, interventional clinical study containing 10 subjects who will be enrolled. Approximately 10 (10) subjects with active anxiety and depression symptoms will receive treatment using the NeuroGlove. Subjects will be recruited in from the community. Inclusion in the study will not impact the care management of the subject. Informed consent will be obtained from all subjects before inclusion in the study.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Anxiety Depression Anxiety Depression Depression, Anxiety

Interventions

NeuroGloveDEVICE

The NeuroGlove is intended to provide peripheral sensory stimulation to the hand through pneumatic puffs of air to encourage collateral blood supply and sensorimotor development.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Able to and willing to provide informed consent. Legally authorized representatives (LARs) will not be allowed to consent on behalf of the subject. * Men and women ≥18 and \<85 years of age. * Carry an active diagnosis of anxiety and/or depression. * Suffer from anxiety and/or depression symptoms that impact subject's daily activities and quality of life. Exclusion Criteria: * Physical limitations of the upper extremity (e.g., fracture, joint deformity, severe spasticity/contracture, wounds, skin breakdown, lymphedema, etc.) * The subject lacks the ability to comprehend or following instructions, or for any reason, in the opinion of the investigator, would be unlikely or unable to comply with study protocol requirements. * Currently participating in another interventional clinical trial. (Observational clinical trial participation is allowed for study enrollment.)

Locations (1)

NeuroGlove

Minneapolis, Minnesota, United States

RECRUITING

Outcomes

Primary Outcomes

Change in anxiety symptoms using GAD-7

The change in symptoms pertaining to anxiety will be evaluated using the change in the GAD-7 score. The GAD-7 is a general anxiety questionnaire with 7 questions. The score ranges from 0 - no anxiety to 21 - severe anxiety.

Time frame: 4 weeks

Change in depression symptoms using PHQ-9

The change in symptoms pertaining to depression will be evaluated using the change in the PHQ-9 score. The PHQ-9 is a general anxiety questionnaire with 9 questions. What does a PHQ-9 score mean? Scores less than 5 often signify the absence of a depressive disorder; scores of 5 to 9 predominantly represented patients with either no depression; depression scores of 10 to 14 represented a spectrum of patients; and scores of 15 or greater usually indicated major depression.

Time frame: 4 weeks

Rate of Adverse Events

Rate and severity of adverse events related to the use of the NeuroGlove assessed by PI during patient interview.

Time frame: 4 weeks

Central Contacts

Thomas Harold

CONTACT

6122550405 info@neuroglove.net

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.